Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T for R/R CD7+ NK/T Cell Lymphoma and Leukemia
NCT04004637Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA3-17 in Natural killer T-cell lymphoma (NKTL), precursor T-cell lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
PA3-17
03
Conditions
Natural killer T-cell lymphoma (NKTL)precursor T-cell lymphoblastic lymphomaacute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04004637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004637.